"Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab." by Jonathan Freeman, MD

Selected Works of Jonathan Freeman MD

Follow Contact

Article

Immunophenotypic changes and clinical outcome in B-cell lymphomas treated with rituximab.

All Scholarly Works

Jonathan Freeman, MD, Baystate Health
Richard Steingart, MD, Baystate Health

Document Type

Article, Peer-reviewed

Publication Date

3-1-2006

Abstract

Rituximab is a chimeric monoclonal antibody that recognizes the CD20 antigen and is used to treat B-cell non-Hodgkin lymphoma (B-NHL). Few studies have been published examining the use of antibody panels to evaluate B-NHL treated with rituximab. The autho

Publication ISSN

0894-1130

Citation Information

Appl Immunohistochem Mol Morphol. 2006 Mar;14(1):18-23.